Table 2.
Evidence-based recommendations for the efficacy of FDA-approved botulinum toxins.6
| Indication | Onabot-A (Botox) | Abobot-A (Dysport) | Incobot-A (Xeomin) | Rimabot-B (Myobloc) |
|---|---|---|---|---|
| Blepharospasm | B | C | B | U |
| Cervical dystonia | B | A | B | A |
| Writer’s cramp | C | C | – | – |
| Spasmodic dysphonia | B | – | – | – |
| Oromandibular dystonia | U | U | – | – |
| Hemifacial spasm | C | C | C | U |
| Palatal myoclonus (tremor) | U | – | – | – |
| Tics | C | – | – | – |
| Essential tremor | C | U | B | – |
| PD rest tremor | C | – | C | – |
| PD camptocormia | U | U | – | – |
| PD levodopa complications | U | U | U | U |
| Restless legs syndrome | U | U | C | – |
| Upper limbs spasticity | A | A | A | B |
| Lower limbs spasticity | A | A | – | U |
OnabotulinumtoxinA (Allergan, Inc., Irvine, CA, USA); abobotulinumtoxinA (Ipsen Biopharm Ltd., Wrexham, UK); incobotulinumtoxinA (Merz Pharmaceuticals GmbH, Frankfurt, Germany); rimabotulinumtoxinB (US WorldMeds, LLC., Louisville, KY, USA).
FDA, Food and Drug Administration; PD, Parkinson’s disease. Level A: effective; Level B: probably effective; Level C: possibly effective; Level U: insufficient evidence.
Table compiled by the authors based on the articles referenced in this article. See Methods section for more detail.